Juvenal Tobin W reported option exercise involving 3,195 derivative units of CASTLE BIOSCIENCES INC at $0.00 for $0 on Nov 11, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Commercial Officer
Chief Commercial Officer
Filed Nov 13, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
3,195Stock option (right to buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
31,805Direct
Trade date
Nov 11, 2026Option exercise
Filed
Nov 13, 2026, 4:05 PM ET2-day reporting delay
Accession
0001628280-26-073814Code M · Transaction 400509
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 11, 2026Option exercise3,195$29.50$94,252.50Trade 400507
Nov 11, 2026Sell3,195$35.07−$112,048.65Trade 400508
3 transaction rows in this filing. Joint filers share the same rows.

CSTL price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
CSTL · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 20, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −5%1w ago +3.6%1d ago −0.2%
Returns since7d30d90d180d1y

Footnotes in full

F1: This transaction was executed in multiple trades at prices ranging from $35.04 to $35.11, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: The shares subject to the option are fully vested.